Alnylam Pharmaceuticals (ALNY)
(Real Time Quote from BATS)
$245.13 USD
+4.98 (2.07%)
Updated Jun 26, 2024 03:46 PM ET
After-Market: $245.72 +0.59 (0.24%) 4:08 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Brokerage Reports
Alnylam Pharmaceuticals, Inc. [ALNY]
Reports for Purchase
Showing records 1 - 20 ( 414 total )
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
AMVUTTRA Launch Exceeding Expectations; HELIOSB Phase 3 Data on Track; Upping PT to $400; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2 KARDIA-2 Data Support Biannual Dosing With Zilebesiran in Hypertension
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Hypertension Program Zilebesiran Clears Phase 2 Hurdle; Announces Initiation of Phase 2 KARDIA-3 Trial; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Statistical Plan Changes in HELIOS-B Positioning AMVUTTRA for Market Leadership in ATTR-CM; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Hepatitis B Breakthrough Boom: Navigating a $450-$500 Billion Frontier
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways from Biotech Breakthroughs ATTR-CM Event: Expect HELIOS-B to Meet Primary, Secondary Endpoints; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department